BRE (brain and reproductive organ-expressed (TNFRSF1A modulator) ) Blocking Peptide (the C terminal of BRE)(100ug)

This is a synthetic peptide designed for use in combination with anti-BRE Antibody (ARP62254_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.

Prices direct from Aviva Systems Biology Incorporated

Quick response times

Exclusive Absave savings/discounts

SPECIFICATIONS

Size

100ug

Reactivities

Hum

Format

Lyophilized powder

Presku

AAP62254

Target

BRE is a component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs). The BRCA1-A complex also possesses deubiquitinase activity that specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX. In the BRCA1-A complex, it acts as an adapter that bridges the interaction between BABAM1/NBA1 and the rest of the complex, thereby being required for the complex integrity and modulating the E3 ubiquitin ligase activity of the BRCA1-BARD1 heterodimer. BRE probably also plays a role as a component of the BRISC complex, a multiprotein complex that specifically cleaves 'Lys-63'-linked ubiquitin. BRE may play a role in homeostasis or cellular differentiation in cells of neural, epithelial and germline origins. BRE may also act as a death receptor-associated anti-apoptotic protein, which inhibits the mitochondrial apoptotic pathway anf regulate TNF-alpha signaling through its interactions with TNFRSF1A; however these effects may be indirect.

Weight

43kDa

Gene Id

9577

Alternative Names

BRCC4; BRCC45